Nonsteroidal anti-inflammatory drugs and the induction of apoptosis in colon cells: Evidence for PHS-dependent and PHS-independent mechanisms

Apoptosis

Volumn 4, Issue 5, 1999, Pages 373-381

  Rigas, Basil ^a   Shiff, S J ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Apoptosis; Carcinogenesis; Colon cancer; Cyclooxygenase; Nonsteroidal anti inflammatory drugs

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLORECTAL CARCINOMA; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; REVIEW;

EID: 0032727613     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009699321946     Document Type: Review

References (61)

1. Shiff SJ, Rigas B. Nonsteroidal anti-inflammatory drugs and colorectal cancer: Evolving concepts of their chemopreventive actions. Gastroenterology 1997; 113: 1992-1998.
2. Levy GN. Prostaglandin H synthases, nonsteroidal anti-inflammatory drugs, and colon cancer. FASEB J 1997; 11: 234-247.
3. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-5589.
4. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature - New Biology 1971; 231: 232-235.
5. Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal anti-inflammatory drugs. Arthritis & Rheumatism 1989; 32: 1-9.
6. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995; 96: 491-503.
7. Shiff SJ, Koutsos M.I, Qiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-188.
8. Hanif R, Pittas A, Feng Y, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996; 52: 237-245.
9. Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci 1994; 107: 3569-3577.
10. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer Cancer Res 1995; 55: 1811-1816.
11. Goldberg Y, Nassif II, Pittas A, et al. The anti-proliferative effect of sulindac and sulindac sulfide on HT-29 colon cancer cells: Alterations in tumor suppressor and cell cycle-regulatory proteins. Oncogene 1996; 12: 893-901.
12. Qiao L, Hanif R, Sphicas E, Shiff SJ, Rigas B. Effect of aspirin on induction of apoptosis in HT-29 human colon adenocarcinoma cells. Biochem. Pharmacol 1998; 55: 53-64.
13. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells - diminished expression of the proliferation markers PCNA and Ki-67. Cancer Lett 1997; 115: 229-234.
14. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide induces several sub-populations of colon cancer cells, defined by PCNA/Ki-67 and DNA strand breaks. Biochimica et Biophysica Acta - Molecular Cell Research. 1997; 1359: 222-232.
15. Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273-2276.
16. Piazza GA, Rahm ALK, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995; 55: 3110-3116.
17. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998; 104: 413-421.
18. Elder DJE, Halton DE, Hague A, Paraskeva C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug - independence from COX-2 protein expression. Clin Cancer Res 1997; 3: 1679-1683.
19. Tsujitani S, Shirai H, Tatebe S, et al. Apoptotic cell death and its relationship to carcinogenesis in colorectal carcinoma. Cancer 1996; 77: 1711-1716.
20. Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-998.
21. Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-366.
22. Winde G, Schmid KW, Brandt B, Muller O, Osswald H. Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. Diseases of the Colon & Rectum 1997; 40: 1156-1168.
23. Winde G, Schmid KW, Schlegel W, Fischer R, Osswald H, Bünte H. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813-830.
24. Aoki T, Boland CR, Brenner DE. Aspirin modulation of premalignant biomarkers in rectal mucosa of high-risk subjects. Gastroenterology 1996; 110: A484.
25. Smith WL, Garavito RM, DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. Journal of Biological Chemistry 1996; 271: 33157-33160.
26. Kutchera W, Jones DA, Matsunami N, et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc Natl Acad Sci USA 1996; 93: 4816-4820.
27. Bennett A, Tacca MD, Stamford IF, Zebro T. Prostaglandins from tumours of human large bowel. Br J Cancer 1977; 35: 881-884.
28. Kubota Y, Sunouchi K, Ono M, Sawada T, Muto T. Local immunity and metastasis of colorectal carcinoma. Diseases of the Colon & Rectum 1992; 35: 645-650.
29. Rigas B, Goldman IS, Levine L. Altered eicosanoid levels in human colon cancer. J Lab Clin Med 1993; 122: 518-523.
30. Nugent KP, Spigelman AD, Phillips RKS. Tissue prostaglandin levels in familial adenomatous polyposis patients treated with sulindac. Diseases of the Colon & Rectum 1996; 39, 659-662.
31. Giardiello FM, Spannhake EW, DuBois RN, et al. Prostaglandin levels in human colorectal mucosa: effects of sulindac in patients with familial adenomatous polyposis. Digestive Diseases & Sciences 1998; 43: 311-316.
32. Yang VW, Shields JM, Hamilton SR, et al. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998; 58: 1750-1753.
33. Rao CV, Rivenson R, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-1472.
34. Qiao L, Kozoni V, Tsioulias GJ, et al. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochimica Biophysica et Acta 1258: 215-223.
35. Bortuzzo C, Hanif R, Kashfi K, Staiano-Coico L, Shiff SJ, Rigas B. The effect of leukotrienes B and selected HETEs on the proliferation of colon cancer cells. Biochimica Biophysica et Acta. 1996; 1300: 240-246.
36. Sheng HM, Shao JY, Morrow JD, Beauchamp RD, Dubois RN. Modulation of apoptosis and bcl-2 expression by prostaglandin E-2 in human colon cancer cells. Cancer Res 1998; 58: 362-366.
37. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and carcinomas. Gastroenterology 1994; 107: 1183-1188.
38. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995; 55: 2556-2559.
39. Tsujii M. and DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493-501.
40. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-809.
41. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 1996; 56: 4566-4569.
42. Sheng H, Shao J, Kirkland SC, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 2254-2259.
43. Thompson HJ, Briggs S, Paranka NS, et al. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J Natl Cancer Inst 1995; 87: 1259-1260.
44. Alberts DS, Hixson L, Ahnen D, et al. Do NSAIDs exert their colon cancer chemoprevention activities through the inhibition of mucosal prostaglandin synthetase. Journal of Cellular Biochemistry-supplement 1995; 22: 18-23.
45. de Mello MC, Bayer BM, Beaven MA. Evidence that prostaglandins do not have a role in the cytostatic action of anti-inflammatory drugs. Biochem. Pharmacol 1980; 29: 311-318.
46. McDougall CJ, Ngoi SS, Goldman IS, et al. Reduced expression of HLA class I and II antigens in colon cancer. Cancer Res 1990; 50: 8023-8027.
47. Tsioulias G, Godwin TA, Goldstein MF, et al. Loss of colonic HLA antigens in familial adenomatous polyposis. Cancer Res 1992; 52: 3449-3452.
48. Tsioulias GJ, Triadafilopoulos G, Goldin E, et al. Expression of HLA class I antigens in sporadic adenomas and histologically normal mucosa of the colon. Cancer Res 1993; 53: 2374-2378.
49. 2 down-regulates the expression of HLA-DR antigen in human colon adenocarcinoma cell lines. Biochemistry 1995; 34: 5604-5609.
50. Arvind P, Qiao L, Papavassiliou ED, Goldin E, Koutsos M, Rigas B. Aspirin and aspirin-like drugs induce the expression of HLA-DR in HT29 colon adenocarcinoma cells. Int J Oncol 1996; 8: 1207-1211.
51. Rigas B, Tsioulias GJ, Allan C, Wali RK, Brasitus TA. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology 1994; 83: 319-323.
52. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994; 79: 1147-1156.
53. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
54. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPAR-gamma enhance colon polyp formation. Nature Med 1998; 4: 1058-1001.
55. + mice. Nature Med 1998; 4: 1053-1057.
56. Sarraf P, Mueller E, Jones D, et al. Differentiation and reversal of malignant changes in colon cancer through PPAR-gamma. Nature Med 1998; 4: 1046-1052.
57. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. Journal of Biological Chemistry 1997; 272: 3406-3410.
58. Schwenger P, Bellosta P, Victor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc. Natl. Acad. Sci. USA 1997; 94: 2869-2873.
59. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Nad. Acad. Sci. USA 1998; 95: 681-686.
60. Takahashi M, Fukutake M, Yokota S, Ishida K, Wakabayashi K, Sugimura T. Suppression of azoxymethane-induced aberrant crypt foci in rat colon by nimesulide, a selective inhibitor of cyclooxygenase 2. J Cancer Res Clin Oncol 1996; 122: 219-222.
61. Rigas B. and Shiff SJ. Is inhibition of cyclooxygenase required for the chemopreventive effect of NSAIDs in colon cancer? A model reconciling the current contradiction. Med Hypotheses 1999; in press.